Coronaviruses and other Novel Antiviral Targets

Prof. Katherine Seley-Radtke group’s NIH-funded research employs a chemical biology approach tonucleoside, nucleotide and heterocyclic drug discovery and development with therapeuticemphasis on antiviral, anticancer and antiparasitic targets and overcoming resistance to currentlyused drugs. Current focus is targeting Ebola, Zika, Dengue and MERS viruses. She has served asthe Program Director for UMBC’s Chemistry-Biology Interface graduate training programfunded by NIH since 2007. This program promotes hands on cross disciplinary research foralmost 50 PhD students from four departments at UMBC and UMB. She is currently theImmediate Past President and Secretary-Elect for the International Society of Nucleosides,Nucleotides and Nucleic Acids and a Board member of the International Society for AntiviralResearch. Prof. Seley-Radtke also serves as a standing member for several NIH study sectionsand is an Associate Editor for three scientific journals – Antiviral Chemistry & Chemotherapy,Molecules – Chemical Biology, and Current Protocols in Chemical Biology.

• 1. Improving properties of the nucleobase analogs T-705/T-1105 as potential antivirals2. Anno 2021: Which antivirals for the coming decade?3. Broad spectrum antiviral fleximer nucleosides4. The search for antivirals to treat alphavirus infections5. Inhibitors of Ebola Virus targeting Innate immune evasion6. Uracil derivatives as non-nucleoside inhibitors of viral infections